All six children with CDA administered varying dosages and frequencies of IFN-α2b showed no favorable effect on hemoglobin, reticulocyte count, or transfusion frequency [96]; however, an adult patient with CDA receiving IFN-α2a achieved a normal range of hemoglobin with markedly reduced CDA-specific dysplasia [97], and an adolescent and an adult patient with CDA I and β thalassemia carriers received IFN-α2b, reducing their transfusion requirements [98]. This evidence concerns the gene CDA and congenital dyserythropoietic anemia.